Cellivery Therapeutics, Inc. Overview
Cellivery Therapeutics was founded in 2014 as a platform biotech built around a protein-delivery technology originally called MITT (Macromolecule Intracellular Transduction Technology) and later rebranded TSDT (Therapeutic Molecule Systemic Delivery Technology), which the company claimed could carry large recombinant proteins across cell membranes and the blood-brain barrier. In November 2018 it became the first company admitted to KOSDAQ under the underwriter-recommended "growth special listing" track, and during the COVID-19 period its market value briefly exceeded KRW 3 trillion on expectations for its Parkinson's candidate iCP-Parkin and anti-inflammatory iCP-NI. No candidate advanced beyond an early Phase 1 trial and no external licensing deal was ever disclosed. After diverting capital-markets proceeds into the acquisition of a wet-tissue maker, the company received consecutive audit disclaimers, was delisted in March 2025, and is now a near-dormant unlisted entity controlled by former minority shareholders.
What the company did (as designed). Cellivery positioned itself as a drug-delivery platform company. Its core claim was that by fusing therapeutic proteins with engineered peptide sequences, it could produce "cell-permeable" recombinant proteins (branded iCP- or CP-) able to enter cells and tissues, including deep brain tissue, which conventional biologics cannot easily reach. Upon IPO in 2018, the prospectus described four protein-based drug candidates — iCP-Parkin (Parkinson's disease), iCP-SOCS3 (pancreatic cancer), CP-BMP2 (bone formation), and CP-ΔSOCS3 (severe obesity) — plus three lines of cell-permeable research reagents (iCP-Cre, six iCP-RF reprogramming factors, and CP-Cas9) (Dailypharm, 9 Nov 2018, citing the investment prospectus).
Business model and revenue model. The intended model was a classic platform-licensing model: (i) out-license individual candidates after preclinical or early clinical proof-of-concept, (ii) non-exclusively license the TSDT platform itself to large pharma partners, and (iii) fund R&D partly through sales of research reagents. In 2017 the company reported revenue of KRW 2.7 bn, operating loss of KRW 3.4 bn and net loss of KRW 3.5 bn, with reagent sales described as a source of self-generated R&D funding (BioSpectator, Sept 2018). In 2016 revenue was KRW 1.3 bn, which management attributed to licensing-related activity (Kormedi report on MJFF grant).
What the company actually became. From November 2021 the revenue base changed fundamentally. Cellivery acquired 100% of Ajin Clean, a wet-tissue and hygiene-products maker founded in 1991, for KRW 14.9 bn, injected a further KRW 14.0 bn of capital, and renamed it Cellivery Living & Health (BizWatch, 18 Jul 2022; Economist Korea, 5 Apr 2023). From FY2022, essentially all consolidated revenue came from this consumer subsidiary (cosmetics, hygiene and lifestyle goods). The parent company's separate revenue was zero in FY2023 and again zero in FY2024 (Dailypharm, 5 Jun 2024; MTN, 21 Feb 2025).
Revenue mix (independent characterisation).
Value-chain position. Pre-2021: discovery and preclinical research, with manufacturing (CMC) and all GLP toxicology and clinical work outsourced to CROs/CMOs in the US, Europe and Asia (Covance/Labcorp, Southern Research, OPIS, KBI). Post-2021: additionally a domestic consumer-goods manufacturer and retailer through the subsidiary.
Customer types and end-markets. Intended: global pharmaceutical companies as licensees (neurology, oncology, immunology/infectious disease). Actual: academic and industrial labs (reagents) and Korean retail consumers (Living & Health products via department stores, duty-free and a flagship store; the premium brand later withdrew from department-store and duty-free channels per Economist Korea, Apr 2023).
Company's own description. The latest annual report language is not available in the sources reviewed. Third-party aggregators summarise the company as developing protein, small-molecule, antibody and vaccine drugs primarily for South Korea, holding US-registered patents, and operating Cellivery Living & Health in beauty and health since January 2022 (roic.ai company profile).
Current operating state (2025–2026). Following delisting, the company is controlled by shareholders who removed the founder. Public reporting in 2026 focuses on the criminal case against former management rather than on any resumed R&D. No active clinical programme, partnership or product revenue at parent level has been publicly disclosed since 2023.
Strategy
Historic stated strategy (2018–2022). Management repeatedly framed the strategy as monetising TSDT through (i) candidate out-licensing, (ii) non-exclusive platform licensing to big pharma, and (iii) fast-tracking iCP-NI into Phase 2 and emergency-use pathways. In October 2019 the CEO told investors he expected a platform deal comparable to or exceeding the Dicerna–Eli Lilly RNAi platform deal (Dealsite, 10 Oct 2019). In 2020 he said an iCP-Parkin licence could be worth trillions of won and a TSDT licence over KRW 1 trillion (Asia Economy, May 2020). None of these deals materialised.
Diversification (2021–2023). Acquisition of Ajin Clean and creation of Cellivery Living & Health, licensing TSDT intra-group for cosmetics and lifestyle products, with a KRW 20 bn annual-revenue target. Prosecutors argued — and the court accepted at first instance — that this pivot was in part a response to the growth-special-listing rule under which a company with annual revenue below KRW 3 bn from its fifth listed year is designated an administrative issue (Bizhankook, Jun 2026).
Survival measures (2023–2024). Objection to delisting and improvement period; promised "normal" trading resumption; claimed negotiations with multiple investors conditional on resolving the governance dispute and extending the improvement period (NewDaily, Mar 2024); addition of automotive-parts trading to business purposes (Etoday, Aug 2024); consideration of winding down Living & Health (Economist Korea, Apr 2023).
Post-delisting strategy (2025–2026). The shareholder-led management's publicly visible priorities have been (i) pursuing criminal and civil accountability of former management, and (ii) preserving the company as an unlisted going concern. Shareholder statements during liquidation trading indicated an intention to accumulate more shares to consolidate control (MTN, Feb 2025). In 2024 the coalition stated a plan to normalise operations and then recruit professional management (NewDaily, Mar 2024). No formal medium-term business plan, R&D restart, financial targets or ESG commitments have been publicly disclosed.
Management guidance / medium-term targets: None publicly disclosed.
Products & Services
5A. Platform technology
MITT → TSDT (Therapeutic Molecule Systemic Delivery Technology). Originally described as Macromolecule Intracellular Transduction Technology (MITT), later branded TSDT; the "TSDT" trademark dates from 2018 (IPqwery). Company claims: enables recombinant proteins to penetrate cell membranes and to pass sequentially cell-to-cell, including across vascular endothelium into brain tissue. The CEO stated at IPO that the technology was the product of roughly 20 years of personal research (BizWatch, Oct 2018). Pricing model: intended licence fees, milestones and royalties; no third-party platform licence ever disclosed.
5B. Drug candidates (by therapeutic area)
| Candidate | Modality / mechanism (company description) | Indication(s) | Highest stage reached | Partners / notes | Key dates |
|---|---|---|---|---|---|
| iCP-Parkin | Cell-permeable recombinant Parkin protein | Parkinson's disease; later claimed Alzheimer's and oncology utility | Preclinical; CMC scale-up at KBI (US CMO) reported 2021 | Co-developed with Ildong Pharmaceutical; MJFF-funded MoA study; patents in AU, EU, JP | Science Advances paper Apr 2020; JP patent Feb 2020 |
| iCP-NI | Cell-permeable protein immunomodulator targeting innate immune/cytokine-storm signalling | COVID-19 severe pneumonia, sepsis, atopic dermatitis, ARDS; inhaled formulation planned for mild COVID | Phase 1 (healthy volunteers) — trial NCT05740280 shows status Terminated | CROs: Covance (tox), Southern Research (efficacy), OPIS (EU/India), Labcorp (US IND) | EU CTA Poland 6 Sep 2021; FDA IND filed 9 Sep 2022, cleared Oct 2022 |
| iCP-SOCS3 | Cell-permeable SOCS3 protein | Pancreatic cancer | Preclinical (primate safety reviewed by prospective licensee) | China rights negotiated with Qilu Pharmaceutical (2019–2020); no deal announced | — |
| CP-FXN | Cell-permeable frataxin protein | Friedreich's ataxia | Preclinical (animal efficacy under milestone 3) | Takeda co-development (from Nov 2018); no licence announced | Milestone 3 contract Jul 2019 |
| CP-BMP2 | Cell- and tissue-permeable bone morphogenetic protein (bio-better) | Bone formation / fractures | Preclinical | EP patent 38 countries | Aug 2020 |
| CP-ΔSOCS3 / CP-SD | Truncated SOCS3 SH2-domain protein | Severe obesity | Preclinical | Patent family filed 2021 | — |
5C. Research reagents (product revenue line pre-2022)
| Product | Description | Status |
|---|---|---|
| iCP-Cre | Cell-permeable Cre recombinase for gene-editing research | Marketed pre-IPO; current status not disclosed |
| iCP-RFs (6 products) | Cell-permeable reprogramming factors | Marketed pre-IPO; current status not disclosed |
| CP-Cas9 | Cell-permeable Cas9 | In development at IPO |
5D. Consumer products (Cellivery Living & Health)
| Line | Description | Status |
|---|---|---|
| Wet tissues / hygiene goods | Legacy Ajin Clean manufacturing business (est. 1991) | Ongoing at last report; subsidiary capital-impaired |
| The Lafuse (더 라퓨즈) | Premium cosmetics brand marketed with TSDT positioning | Withdrew from department stores and duty-free (Apr 2023) |
| Celli Lounge | Flagship store, Garosu-gil, Gangnam, Seoul | Opened 2022; continuity uncertain (Apr 2023) |
| Bioneul (바이오늘) | Lifestyle/health business line | Described as uncertain (Apr 2023) |
| Health functional foods | Planned entry from 2023 | No evidence of launch |
Pricing models for consumer products: not publicly disclosed. Target annual revenue of KRW 20 bn was stated by management in January 2022 (Dailypharm related headline; Dealsite related headline).
Financial Narrative
Data quality warning. FY2019–FY2021 figures are from audited statements; FY2022 and FY2023 statements carry disclaimers of opinion (audit scope limitation, going-concern uncertainty, and questions over the appropriateness of investment and fund transactions). FY2024 consolidated annual figures and FY2025 statements are not publicly available in the sources reviewed. All figures are consolidated, IFRS, KRW millions unless stated. Primary aggregator: Stockopedia (sourced from annual audited accounts).
6A. Income statement
Operating income FY2019–FY2022 by year: not publicly disclosed in sources reviewed; cumulative consolidated operating loss FY2021–FY2023 was KRW 114.5 bn, implying combined FY2021+FY2022 operating losses of approximately KRW 94.9 bn (Dailypharm, 5 Jun 2024).
Gross profit, EBITDA, EPS (basic/diluted), dividends per share: not publicly disclosed in sources reviewed. Dividends: none ever paid.
6B. Margins (computed from 6A)
Revenue CAGR FY2019–FY2023: approx. 73.7% per year, computed. This figure is not indicative of organic growth: the step-change in FY2022 reflects consolidation of the acquired wet-tissue business, while parent-level pharmaceutical revenue fell to zero.
6C. Trailing-twelve-month trajectory
Note the internal inconsistency in the aggregator series (LTM revenue at Sep-2023 of KRW 39.1 bn exceeding the FY2023 total of KRW 18.9 bn), which likely reflects restatement or reclassification within disclaimed statements. Both figures are shown as reported; the discrepancy is unresolved.
6E. Cash flow and capital raising
Pre-IPO and IPO funding (KRW bn).
PitchBook additionally lists PIPE transactions dated 19 Aug 2020, 1 Oct 2021, and 15 Oct 2021 (the last at USD 16.5 m) and cumulative funding of USD 74.2 m.
6F. Ratios
ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle: not meaningful / not publicly disclosed. Equity approached zero by mid-2023 and EBITDA was persistently negative, rendering leverage and return ratios mathematically meaningless. Simply Wall St reports return on equity as "n/a".
6G. Commentary
The five-year record shows a pre-revenue biotech whose losses roughly doubled from FY2020 to FY2021 and then more than doubled again in FY2022 to a net loss of KRW 75.2 bn, the inflection coinciding with the pandemic-era equity surge, aggressive stock-option exercises, the capital raise of September 2021, and the consolidation of a loss-making consumer subsidiary. The FY2022 spike in general and administrative expense (LTM KRW 44.4 bn versus R&D of KRW 19.1 bn per Simply Wall St) indicates that the cost base grew far more on overhead and the subsidiary than on research. FY2023 losses contracted to KRW 32.6 bn largely because the organisation was dismantled: headcount went from 100 to 9 within a year, and the parent generated no revenue. By the September 2024 LTM point, net losses were down to KRW 6.1 bn on revenue of KRW 8.8 bn, a shrinkage consistent with wind-down rather than recovery. The company's revenue never came from its claimed core technology in any meaningful, third-party-validated way.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Units
| Unit | Legal entity | Contents | Status |
|---|---|---|---|
Pharmaceutical R&D (parent) | Cellivery Therapeutics, Inc. | TSDT platform, drug candidates (iCP-Parkin, iCP-NI, iCP-SOCS3, CP-FXN, CP-BMP2, CP-ΔSOCS3), research reagents | Separate revenue zero in FY2023 and FY2024; no tangible assets beyond fixtures reported by early 2025 (MTN) |
Consumer / Living & Health | Cellivery Living & Health Co., Ltd. (formerly Ajin Clean, est. 1991) | Wet tissues, hygiene products, cosmetics ("The Lafuse"), flagship store "Celli Lounge", planned health-functional foods; "Bioneul" business line | 100% owned at acquisition; fully capital-impaired; FY2022 operating loss KRW 28.5 bn and net loss KRW 30.6 bn; FY2022 audit disclaimed (Economist Korea, Apr 2023) |
Revenue by Segment
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Consolidated revenue (KRW Mn) | 3,872 | 23,158 | 18,863 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Revenue
| Metric | FY2023 | FY2024 |
|---|---|---|
Parent-company separate revenue (KRW Mn) | 0 | 0 |
Income Statement
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 2,074 | 762 | 3,872 | 23,158 | 18,863 |
Pre-tax income (KRW Mn) | -19,577 | -17,937 | -29,682 | -75,018 | -34,007 |
Net income after taxes (KRW Mn) | -19,650 | -17,248 | -28,069 | -75,159 | -34,036 |
Net income attributable to owners (KRW Mn) | -19,650 | -17,248 | -28,069 | -75,159 | -32,571 |
Metric | FY2023 | — | — | — | — |
Consolidated operating income (KRW Mn) | -19,600 | — | — | — | — |
Parent separate operating income (KRW Mn) | -11,900 | — | — | — | — |
Margin Analysis (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Pre-tax margin (%) | -943.9 | -2,354.0 | -766.6 | -323.9 | -180.3 |
Net margin attributable (%) | -947.4 | -2,263.5 | -724.9 | -324.6 | -172.7 |
Metric | FY2023 | — | — | — | — |
Operating margin consolidated (%) | -103.9 | — | — | — | — |
Income Statement (Dec-2021–Sep-2024)
| Metric | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LTM revenue (KRW Mn) | 3,872 | 4,008 | 4,223 | 4,306 | 23,158 | 30,457 | 34,994 | 39,130 | 18,863 | 14,494 | 11,193 | 8,831 |
LTM net income (KRW Mn) | -28,069 | -31,276 | -32,762 | -30,831 | -75,159 | -82,316 | -85,507 | -83,317 | -32,571 | -20,314 | -9,429 | -6,127 |
Financial Analysis
| Item | Latest disclosed data point | Source |
|---|---|---|
Cash & equivalents | Defence counsel stated the company had about KRW 45 bn of liquid assets in Sept 2021; prosecution stated only about KRW 7.2 bn was in ordinary deposits, the rest tied in short-term instruments | Bizhankook, Jun 2026 |
Total debt | Convertible bonds outstanding with put option exposure of approx. KRW 35 bn cited as a factor in the FY2022 disclaimer | MT, 13 Oct 2023 |
Equity | H1 2023 equity below KRW 1 bn; capital impairment ratio ≥50% | Dealsite, 23 Aug 2023 |
Tangible assets (parent) | By early 2025 consisted only of office fixtures | MTN, 21 Feb 2025 |
Buybacks | None identified | — |
Equity/convertible raised Sept 2021 | Approx. KRW 69.9–70 bn via convertible bonds and related issuance, disclosed for R&D; court found funds were used for Ajin Clean acquisition and related purposes | MTN; Bizhankook 2026 |
Unsecured loans to subsidiary | Approx. KRW 20.3 bn lent to Living & Health without collateral | MTN, Jun 2026 |
Capital injection into subsidiary | KRW 14.0 bn | BizWatch 2022 |
Round Details
| Round | Year | Amount (KRW Bn) | Key investors |
|---|---|---|---|
Series A | 2015 | 5.0 | SBI Investment, CKD Venture Capital, Platinum Technology Investment |
Series B | 2017 | 8.5 | Ildong Pharmaceutical, Dongbu Securities, SBI Investment |
Pre-IPO | 2018 | 7.0 | Not itemised |
IPO | 2018 | Up to 28.4 at KRW 25,000/share (band implied KRW 22.7–28.4 bn) | Public; lead manager DB Financial Investment |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
South Korea — consolidated revenue, inferred (KRW Mn) | 3,872 | 23,158 | 18,863 |
Market Valuation
| Metric | 2020-01-02 | 2020-08-13 | 2021-01-28 | 2023-03-23 | 2025-03 |
|---|---|---|---|---|---|
Market capitalisation (KRW Bn) | 484.8 | 1,000 | 3,142.3 | 244.3 | 2 |
Share Price
| Metric | IPO Nov 2018 | 2020-04-01 | 2023-03 suspension | 2025-03 post-liquidation |
|---|---|---|---|---|
Share price (KRW) | 25,000 | 84,700 | 6,680 | 60 |
Capital Markets
| Item | Status |
|---|---|
Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B) | Not meaningful (negative earnings and equity; no market price) |
Analyst consensus | None; aggregators report zero analysts |
Dividend history and policy | No dividends ever paid |
Buyback authorisations | None identified |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | Not publicly disclosed; CB put exposure approx. KRW 35 bn referenced in 2023 |
Unlisted-market status | Seoul Exchange trading support terminated pending prior-year audit report |
Analyst Conclusions
Management guidance. None publicly disclosed since the April 2025 change of control.
Consensus growth expectations. None; no analyst coverage.
Bull case (low probability)
-
IP monetisation: If the iCP-Parkin and iCP-SOCS3 patent families remain in force, a sale to a delivery-platform developer could return some value to an equity base of 37.2 m shares that currently has no market price.
-
Recoveries from former management: A first-instance conviction (Aug 2026) accepting that approx. KRW 70 bn was misused strengthens the company's standing to pursue civil recovery against convicted executives.
-
Cost discipline under shareholder control: Losses had already contracted to an LTM KRW 6.1 bn by Sept 2024; an aligned owner-manager may run the shell at minimal cost while pursuing recoveries and asset sales.
Bear case (base case)
-
No operating business at parent: Separate revenue of zero in FY2023 and FY2024 and a staff of single digits mean there is no R&D engine to restart.
-
Liabilities and subsidiary losses: A capital-impaired subsidiary, unsecured intra-group loans of KRW 20.3 bn, and historic CB obligations point toward restructuring or liquidation rather than revival.
-
Recoveries likely limited: The court cut forfeiture from the KRW 67.7 bn sought to about KRW 0.5 bn, and the large fines accrue to the state, not the company; competing claims from ~50,000 shareholders further dilute any recovery.
Catalysts and monitorables (next 12 months)
-
Whether Cho and Kwon appeal, and the appellate timeline at the Seoul High Court.
-
Filing of FY2025 audited financial statements (required for resumption of unlisted trading on Seoul Exchange).
-
Status of the patent estate (maintenance, assignment, encumbrance).
-
Disposition of Cellivery Living & Health (sale, liquidation or rehabilitation).
-
Outcomes of shareholder civil suits and any corporate damages claim against former officers.
-
Any formal insolvency or rehabilitation filing by the parent.
Analyst verdict
Cellivery Therapeutics is no longer an investable operating company; it is a post-delisting legal and asset-recovery situation. Its history is a case study in how a pre-revenue platform biotech can reach a multi-trillion-won valuation on press-released preclinical claims and unnamed partnership discussions without ever producing a third-party licence or meaningful clinical data. Between its November 2018 listing as the first growth-special-listing company and its March 2025 delisting, the company's only material revenue came from a wet-tissue and cosmetics business acquired in November 2021 — an acquisition that a Korean court has now found, at first instance, was funded with roughly KRW 70 bn raised from investors on the representation that it would finance drug development.
The quantitative record supports this reading. General and administrative expense exceeded R&D in every year with data, peaking at KRW 44.4 bn against KRW 19.1 bn of R&D in FY2022. Net losses reached KRW 75.2 bn in FY2022, and the two subsequent annual audits ended in disclaimers. Headcount fell from 100 to 9 within twelve months, and parent revenue fell to zero.
The April 2025 transfer of control to the minority shareholders' coalition and the August 2026 conviction of the founder close the governance chapter but do not restore an enterprise. The remaining value, if any, lies in the patent estate, possible civil recoveries, and the disposal of the consumer subsidiary — each uncertain in existence, timing and magnitude, and none disclosed in auditable form. Absent a credible audited FY2025 balance sheet and a disclosed plan for the IP, the rational base case is that equity holders recover little or nothing. For market participants and policymakers, Cellivery's enduring significance is as the precedent behind Korea's 2025 tightening of delisting rules and the heightened scrutiny of special-listing biotech disclosures.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Yoon Ju-won (윤주원) | CEO / Representative Director | Since April 2025 EGM | Leader of the Cellivery minority shareholders' coalition (2,772 shareholders, 26.41% stake in 2024–25); a retail shareholder who stated his retirement savings were tied up in the stock |
Board of Directors
| Name | Former role | Notes |
|---|---|---|
Cho Dae-woong (조대웅) | Founder, CEO, largest shareholder (13.32% personally; 13.88% with related parties as of Mar 2024) | Convicted at first instance 20 Aug 2026: 15 years' imprisonment, KRW 210 bn fine, forfeiture of approx. KRW 517.28 m; bail revoked and detained in court. |
Kwon Seon-hong (권선홍) | Former CFO / inside director | Convicted at first instance 20 Aug 2026: 5 years, KRW 110 bn fine |
Kim Hyung (김형) | Head of Strategic Planning; elected inside director at 29 Mar 2024 AGM | Current status not disclosed |
Baek Yung-ki (sources also spell "Park Yung-ki") | Outside director; removal proposed by shareholders Mar 2024 | Name spelling discrepancy between NewDaily and Hankyung reports |
Lee Jae-man (이재만) | Described as second-largest shareholder; briefly a non-standing management adviser; shareholder-nominated director candidate in 2024 | NewDaily, Mar 2024 |
Unnamed "Executive Choi" | Former registered executive (resigned Apr 2021) | Received KRW 23.6 bn in H1 2021 compensation, of which KRW 23.48 bn was stock-option exercise gain (Dailypharm) |
Unnamed "Executive Kwon" | Executive | KRW 2.03 bn stock-option gain in H1 2021 |
Unnamed "Auditor Lee" | Statutory auditor | KRW 1.01 bn stock-option gain in H1 2021 |
Unnamed former Vice President | Former VP | Summarily indicted Oct 2023 alongside Cho |
Major Shareholders
| Holder | Stake | Date / source |
|---|---|---|
Minority shareholders' coalition (aggregated proxies) | 26.41% (2,772 members) | MTN, Feb 2025; NewDaily, May 2024 |
Cho Dae-woong | 13.32% | NewDaily, Mar 2024 |
Cho + related parties | 13.88% | NewDaily, Mar 2024 |
Cho and spouse shares subject to forced liquidation (margin calls) | Approx. 5.1 m shares expected to be sold in liquidation trading | MTN, Feb 2025 |
Pre-IPO institutions (SBI Investment, CKD VC, NH Investment & Securities, Korea Securities Finance, Dongbu Securities) | 38.6% combined | NewDaily, Sept 2018 (historic) |
Total shareholders | Approx. 50,000, claiming aggregate losses above KRW 1 trillion | Bizhankook, Jun 2026 |
Competitive Landscape
Competitors by Segment
| Arena | Named competitors | Relative positioning vs Cellivery |
|---|---|---|
BBB shuttle / brain delivery platforms | Roche (Brainshuttle), Denali Therapeutics (Transport Vehicle), ABL Bio (Grabody-B, Korea) | Competitors validated platforms via clinical data and/or licensing deals with large pharma; Cellivery's claims remained preclinical and unpartnered |
Intracellular delivery of large molecules | Entrada Therapeutics (EEV), PepGen (EDO), Sarepta (PPMO), Dicerna (RNAi platform, licensed to Eli Lilly — cited by Cellivery's CEO as benchmark) | Competitors reached human trials or major platform deals |
Korean platform biotechs | Alteogen (subcutaneous formulation platform), LigaChem Biosciences (ADC platform), ABL Bio | All achieved multi-billion-dollar global licensing; Cellivery achieved none |
Parkinson's disease-modifying | Roche/Prothena (prasinezumab), Biogen (cinpanemab), Kainos Medicine (Korea) | Cellivery itself noted both antibodies failed Phase 2 (MT, May 2021); Cellivery never entered clinic for Parkinson's |
COVID-19 / cytokine storm | Dexamethasone (standard of care), Roche (tocilizumab), Eli Lilly (baricitinib) | Approved agents dominated; iCP-NI Phase 1 terminated |
Korean special-listing biotech cohort (failed) | PharmAbcine, Olipass (both delisted 2025) | Same fate; Cellivery was first |
Recent Developments
Because the strict 18-month window (April 2025 – October 2026) contains limited corporate activity, the register is extended back to March 2023 to capture the full sequence of material events.
Appeal filings following the 20 August 2026 verdict: not confirmed in sources reviewed.



